Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] Journal article | | Title | Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer. | | Author(s) | Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP | | Institution | Authors' Affiliations: Dana-Farber Cancer Institute; Harvard Medical School; Dana-Farber/Harvard Cancer Center; Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Defense Prostate Cancer Clinical Trials Consortium, New York, NY; Sunnybrook Health Science Centre, Toronto, Ontario, Canada; Oregon Health and Science University, Knight Cancer Institute, Portland, Oregon; M. D. Anderson Cancer Center, Houston, Texas; Johns Hopkins University School of Medicine, Baltimore, Maryland; Tulane Cancer Center, New Orleans, Louisiana; and GlaxoSmithKline, Research Triangle Park, North Carolina. | | Source | Clin Cancer Res 2009 Nov 3. | | Abstract | PURPOSE: Increasing evidence indicates that enhanced intratumoral androgen synthesis contributes to prostate cancer progression after androgen deprivation therapy. This phase II study was designed to assess responses to blocking multiple steps in androgen synthesis with inhibitors of CYP17A1 (ketoconazole) and type I and II 5alpha-reductases (dutasteride) in patients with castration-resistant prostate cancer (CRPC). EXPERIMENTAL
DESIGN: Fifty-seven men with CRPC were continued on gonadal suppression and treated with ketoconazole (400 mg thrice daily), hydrocortisone (30 mg/AM, 10 mg/PM), and dutasteride (0.5 mg/d).
RESULTS: Prostate-specific antigen response rate (>/=50% decline) was 56% (32 of 57; 95% confidence interval, 42.4-69.3%); the median duration of response was 20 months. In patients with measurable disease, 6 of 20 (30%) responded by the Response Evaluation Criteria in Solid Tumors. Median duration of treatment was 8 months; 9 patients remained on therapy with treatment durations censored at 18 to 32 months. Median time to progression was 14.5 months. Grade 3 toxicities occurred in 32% with only one reported grade 4 (thrombosis) toxicity. Dehydroepiandrosterone sulfate declined by 89%, androstenedione by 56%, and testosterone by 66%, and dihydrotestosterone declined to below detectable levels compared with baseline levels with testicular suppression alone. Median baseline levels and declines in dehydroepiandrosterone sulfate, androstenedione, testosterone, and dihydrotestosterone were not statistically different in the responders versus nonresponders, and hormone levels were not significantly increased from nadir levels at relapse.
CONCLUSION: The response proportion to ketoconazole, hydrocortisone, and dutasteride was at least comparable with previous studies of ketoconazole alone, whereas time to progression was substantially longer. Combination therapies targeting multiple steps in androgen synthesis warrant further investigation. (Clin Cancer Res 2009;15(22):7099-105). | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19887483 |
|
|
| |
Advertise on this site.
| | |
|
